Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Silence Therapeutics (SLN) over the last 6 years, with Q3 2025 value amounting to $40.4 million.

  • Silence Therapeutics' Net Cash Flow rose 17309.18% to $40.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 11929.02%. This contributed to the annual value of $52.5 million for FY2024, which is 116348.37% up from last year.
  • Per Silence Therapeutics' latest filing, its Net Cash Flow stood at $40.4 million for Q3 2025, which was up 17309.18% from -$23.4 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Net Cash Flow ranged from a high of $74.9 million in Q1 2024 and a low of -$56.7 million during Q1 2025
  • For the 5-year period, Silence Therapeutics' Net Cash Flow averaged around $2.6 million, with its median value being -$4.3 million (2024).
  • The largest annual percentage gain for Silence Therapeutics' Net Cash Flow in the last 5 years was 1670649.72% (2022), contrasted with its biggest fall of 125310.96% (2022).
  • Quarter analysis of 5 years shows Silence Therapeutics' Net Cash Flow stood at $3.0 million in 2021, then crashed by 1253.11% to -$34.9 million in 2022, then surged by 72.37% to -$9.6 million in 2023, then soared by 499.44% to $38.5 million in 2024, then grew by 4.78% to $40.4 million in 2025.
  • Its last three reported values are $40.4 million in Q3 2025, -$23.4 million for Q2 2025, and -$56.7 million during Q1 2025.